How to optimise treatment compliance in metastatic renal cell carcinoma with targeted agents

Annals of Oncology

Volumn 20, Issue SUPPL.1, 2009, Pages

  Ravaud, A ^a,b  

^a HÔPITAL SAINT ANDRÉ   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Adverse events; Management; Metastatic renal cell carcinoma; Targeted agents; Treatment compliance

Indexed keywords

ARTICLE; DOSE RESPONSE; DRUG THERAPY; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; METASTASIS; METHODOLOGY; PATIENT COMPLIANCE;

CARCINOMA, RENAL CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY; HUMANS; KIDNEY NEOPLASMS; PATIENT COMPLIANCE;

EID: 66549084593     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp073     Document Type: Conference Paper

References (24)

1. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134.
2. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alpha-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-2111.
3. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281.
4. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124.
5. Ljungberg B, Hanbury FC, Kuczyk MA et al. Guidelines on Renal Cell Carcinoma. Update March 2007 http://www.uroweb.org/fileadmin/user_upload/Guidelines/08_Renal_Cell_Car cinoma_2007(accessed 3 August 2008).
6. National Comprehensive Cancer Network. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer v.1 2008 http://www.nccnorg/professionals/physician_gls/PDF/kidneypdf2008.
7. Figlin RA, Hutson TE, Tomczak P et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol 2008; 26 (May 20 Suppl): Abstr 5024; Oral presentation.
8. Sternberg CN. Expanding the boundaries of clinical practice: building on experience with targeted therapies. Ann Oncol 2009; 20 (Suppl 1): i1-i6.
9. Houk B, Bello CL, Michaelson MD et al. A population pharmacokinetic/pharmacodynamic (PK/PD) analysis of exposure-response for sunitinib in metastatic renal cell carcinoma (mRCC). Eur J Cancer 2007; 5 (Suppl): 299 (Abstr 4.505) Oral presentation.
10. Pfizer Inc. Data on file.
11. Amato RJ, Harris P, Dalton M et al. A phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC). J Clin Oncol 2007; 25 (June 20 Suppl): Abstract 5026.
12. Amato RJ, Jac J, Harris P et al. A phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC). J Clin Oncol 2008; 26 (May 20 Suppl): Abstr 5122.
13. Atkins MB, Hidalgo M, Stadler W et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22: 909-918.
14. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-456.
15. Rini BI, Halabi S, Rosenberg JE et al. CALGB 90206: A phase III trial of bevacizumab plus interferon-alfa versus interferon-alpha monotherapy in metastatic renal cell carcinoma. Oral presentation at the American Society of Clinical Oncology Genitourinary Cancers Symposium. San Francisco, CA, USA February 14-16, 2008 (Abstr 350).
16. Porta C, Szczylik C, Bracarda S et al. Short- and long-term safety with sunitinib in an expanded access trial in metastatic renal cell carcinoma. J Clin Oncol 2008; 26 (May 20 Suppl): Abstr 5114; Poster presentation.
17. Naito S, Tsukamoto T, Murai M et al. Clinical benefits of long-term use of sorafenib in Japanese patients with unresectable renal cell carcinoma (RCC). J Clin Oncol 2008; 26 (May 20 Suppl): Abstr 16039.
18. Ravaud A, Bajetta E, Bracarda S et al. Long-term tolerability of first-line bevacizumab (BEV) administered for >12 months to patients (pts) with metastatic renal cell carcinoma (mRCC). Ann Oncol 2008; 19 (Suppl 8): 579O Oral presentation.
19. Rini BI, Tamaskar I, Shaheen P et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007; 99: 81-83.
20. Tamaskar I, Bukowski R, Elson P et al. Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann Oncol 2008; 19: 265-268.
21. Wolter P, Stephan C, Decallonne B et al. Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients (pts) with advanced renal cell cancer (RCC). J Clin Oncol 2008; 26 (May 20 Suppl): Abstr 5126.
22. Rini BI, Schiller JH, Fruehauf JP et al. Association of diastolic blood pressure (dBP) >90 mmHg with overall survival (OS) in patients treated with axitinib (AG- 013736). J Clin Oncol 2008; 26 (May 20 Suppl.): Abstract 3543; Poster presentation.
23. ® (sunitinib): Summary of Product Characteristics January 2008.
24. ® (sorafenib) Summary of Product Characteristics April 2008.